Compare Quest Diagnostics Inc (DGX) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Li Auto Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Li Auto Inc trades at $11.54 (market cap $10.71B). The key difference: Quest Diagnostics Inc is far larger — about 2.4× Li Auto Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Li Auto Inc for 101 Days on average.
| DGX | LI | |
|---|---|---|
Market Cap | $25.48B | $10.71B |
Volume | 941,866 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $23.13 |
52-Week Low | $173.49 | $10.69 |
Typical Hold Time | 56 Days | 101 Days |
Enterprise Value | $31.23B | $139.58M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows, reflecting bearish technical signals and recent earnings misses. The company reported declining revenue ($112.31B in 2025) and negative net income margins (-4.4%), though valuation metrics like P/S (0.73) appear attractive. Recent news highlights delivery moderation and new model launches (Li i9, Li MEGA) amid intense EV competition.
The stock faces near-term headwinds from cash burn and competitive pressures, but analyst consensus remains cautiously optimistic with a $15.18 price target. Key risks include execution challenges in global expansion and margin recovery, while potential upside hinges on successful product cycles and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
